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ABSTRACT In our work the antitumor and antimetastatic activities of RNase A and DNase I were studied using two 
murine models of pulmonary (Lewis lung carcinoma) and liver (hepatoma A-1) metastases. We found that intramus-
cular administration of RNase A at the dose range of 0.1–50 µg/kg retarded the primary tumor growth by 20–40%, and 
this effect disappeared with the increase in RNase A dose over 0.5 mg/kg. DNase I showed no effect on the primary 
tumor growth. The intramuscular administration of RNase A (0.35–7 µg/kg) or DNase I (0.02–2.3 mg/kg) resulted in a 
considerable decrease in the metastasis number into the lungs of animals with Lewis lung carcinoma and a decrease of 
the hepatic index of animals with hepatoma 1A. A histological analysis of the organs occupied by metastases revealed 
that the administration of RNase A and DNase I induced metastasis pathomorphism as manifested by the destruction 
of oncocytes, an increase in necrosis and apoptosis foci in metastases, and mononuclear infiltration. Our data indicated 
that RNase A and DNase I are highly promising as supplementary therapeutics for the treatment of metastasizing 
tumors.
KEYWORDS antimetastatic activity, DNase I, RNase A, Lewis lung carcinoma, hepatoma 1A.
ABBREVIATIONS LLC – Lewis lung carcinoma, HA-1 – hepatoma 1A.
INTRODUCTION
Recent data on the implication of small noncoding RNAs in 
tumorigenesis [1–3] and tumor-derived DNAs in metastasis 
progression (genometastasis hypothesis) [4] gave a new initia-
tive to the study of enzymes cleaving nucleic acids as poten-
tial antitumor and antimetastatic agents.
Extensive studies on the antitumor potential of exogenous 
ribonucleases are being conducted worldwide. The high an-
titumor activity of the RNase A family members BS-RNase 
[5–8] and onconase [9–11] has been shown. Of this family, 
RNase A was first studied for antitumor activity [12–14]. The 
data of these experiments were contradictory. Some authors 
reported high antitumor activity in RNase A [12, 13], whereas 
others reported its complete absence [14, 15]. The absence 
of any antitumor effect of RNase A was attributed to its in-
activation by ribonuclease inhibitor [16, 17]; both onconase 
and BS-RNase can avoid interaction with the inhibitor, thus 
keeping their cytotoxic activity against tumor cells [18–20]. 
The antimetastatic potential of DNase I was demonstrated 
in vivo using a L5178Y-ML liver metastasis model [21, 22]. 
However, the use of DNase I as an adjuvant in cancer therapy 
was not further extended.
In this work we studied the antitumor and antimetastatic 
effects of RNase A and DNase I on two murine tumor models: 
Lewis lung carcinoma (LLC) metastasizing to the lungs and 
hepatoma A-1 (HA-1) metastasizing to the liver. The intra-
muscular administration of RNase A at a dose ranging within 
0.1–50 g/kg resulted in the retardation of tumor growth by 
20–40%. The administration of either RNase A or DNase I led 
to a two- to threefold decrease in the number of metastases 
in the lungs (LLC) or a decrease of the hepatic index (HA-1). 
A histological analysis revealed the destruction of tumor cells, 
an increase in the number of necrotic and apoptotic sections 
in metastatic foci, and mononuclear infiltration following 
treatment with the enzymes.
MATERIALS AND METHODS
RNase A (mol. wt 13,700) and DNase I (2.155 kU/mg) from 
bovine pancreas were purchased from Sigma (United States); 
[γ-32P]adenosine-5’-triphosphate ([γ-32P]ATP) (3,000 Ci/
mmole) was purchased from Biosan (Russia), and T4 poly-
nucleotide kinase was purchased from Fermentas (Lithuania). 
The pHIV-2 plasmid was kindly provided by Prof. Hans J. 
Gross (University of Wuerzburg, Wuerzburg, Germany).
LLC and HA-1 tumor strains were obtained from the vi-
varium at the Institute of Cytology and Genetics, Siberian 
Branch, Russian Academy of Sciences (SB RAS), Novosibirsk, 
Russia.
The HIV-1 RNA fragment prepared by in vitro transcrip-
tion was labeled at the 5’-end using γ-32P ATP and T4-poly-
nucleotide kinase [23].
Determination of RNase A activity. A reaction mixture (10 l 
total volume) containing 50 000 cpm of 5’-[32P]-labeled RNA, 
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1 mM EDTA, and 100 g/ml of RNA carrier was incubated 
at 37°C for 1–15 min. Following incubation, the reaction mix-
tures were extracted with phenol and RNA was precipitated 
from an aqueous phase with 96% ethanol. The products of 
RNA cleavage were analyzed by electrophoresis in 12% de-
naturing polyacrylamide gel. 
Determination of DNase I activity. A reaction mixture (10 l 
total volume) containing 0.2 g of pHIV-2 plasmid DNA, 0.01–
1 U of DNase I, 10 mM Tris-HCl, pH 7.5, 2.5 mM MgCl2, and 
0.1 mM CaCl2 was incubated at 37°C for 1–15 min. The reac-
tion was quenched by heating at 60°C for 10 min. The prod-
ucts of DNA cleavage were analyzed by electrophoresis in 1% 
agarose gel. 
Tumor models. Female C57Bl/6 mice (10–11 week-old) and fe-
male A/Sn mice (12–14 week-old) were housed in plastic cages 
(8–10 animals per cage) under normal daylight conditions. Wa-
ter and food were provided ad libitum. All procedures with the 
animals were carried out according to approved methods and 
recommendations for laboratory-animal care [European Com-
munities Council Directive 86/609/CEE].
Solid LLC or HA-1 tumor development was generated by 
injecting corresponding tumor cells (106 cells per animal) into 
the femoral muscle of С57Bl/6J or A/Sn mice, respectively.
Intramuscular administration of RNase A and DNase I and 
an examination of their effect on the primary tumor and 
metastases. On day 4 or 8 after the implantation of LLC tu-
mor cells, C57Bl/6J mice were divided into groups and intra-
muscular injections were performed daily as follows: group 
1 (control) received saline and groups 2–9 received 0.1 ml of 
RNase A saline solution (0.1, 0.5, 1, 10, and 50 g/kg and 0.5, 
1 and 10 mg/kg, respectively); groups 10–13 received 0.1 ml 
of DNase I saline solution (0.02, 0.23, 1.15, and 2.3 mg/kg, re-
spectively).
On day 8 after the implantation of НА-1 tumor cells, A/
Sn mice were divided into groups and intramuscular injec-
tions were performed daily as follows: group 1 (the control) 
received saline and groups 2–4 received 0.1 ml of RNase A 
saline solution (0.35, 0.7 and 7 g/kg, respectively); groups 
5–9 received  0.1 ml of DNase I saline solution (0.02, 0.23, 1.15, 
and 2.3 mg/kg, respectively).
During the experiment, animals were injected 8–10 
times with either enzyme solution or saline. The tumor 
size was measured every three days with calipers, and 
the tumor volume was calculated from the equation V = 
(π/6 × length × width × height) [24].
On day 20 after tumor implantation, the mice were killed 
by cervical dislocation. Livers of A/Sn mice with HA-1 were 
weighed, and the hepatic index (HI) was calculated from the 
equation HI = (liver weight/body weight)  100%. The aver-
age liver increment (ALI) during tumor development was 
calculated by the subtraction of healthy animals’ HI (4.5% 
for A/Sn mice) from the mean HI of the experimental group. 
Therapeutic efficacy (TE) was calculated from the equation 
TE (%) = 100 – ALIexp / ALIcontrol  100%.
The lungs of animals with LLC and liver of animals with 
НА-1 were fixed in 4% formaldehyde for further histological 
analysis. The number of metastases in the lungs of LLC-bear-
ing mice was enumerated using a binocular microscope.
Histological analysis. Fixed lungs and liver were treated ac-
cording to routine protocol and embedded in paraffin. Histo-
logical sections (5-m-thick) were prepared on a microtome 
and stained with hematoxylin and eosin (HE staining). Patho-
morphological features were evaluated visually using an Ax-
ioimager Z microscope (Zeiss).
Statistical analysis. Whenever the data showed normal distri-
bution, their statistical processing was performed using Stu-
dent’s t-test. Otherwise, the Mann-Whitney nonparametric 
statistics was used. Differences were regarded as significant 
at p < 0.05.
RESULTS AND DISCUSSION
Choice of Dose Ranges for RNase A and DNase I Used in Ex-
periments In Vivo.
Since the enzymatic activities of RNase A and DNase 
I were assumed to be essential for the antitumor effect of 
these enzymes, concentrations which provide a 50% cleavage 
of substrates in a relatively short time were determined in 
experiments in vitro.
To do this, [5’-32P]RNA (10-5M) was incubated in the pres-
ence of 10-10–10-7M RNase A at 37°C for 1–15 min. Kinetics of 
RNA cleavage has shown a 50% cleavage of the substrate in 
10 min at a RNase A concentration of 10-9 M. Similarly, 50% 
cleavage of DNA substrate was achieved in 1 min by 10 U of 
DNase I per ml. These concentrations of RNase A and DNase 
I were taken as the starting points to select the appropriate 
doses of the enzymes for the in vivo assay.
EFFECTS OF RNASE A AND DNASE I ON 
PRIMARY TUMOR GROWTH
Intramuscular administration of RNase A to LLC-bearing 
C57Bl/6J mice. The effect of RNase A on the primary tu-
mor growth was examined in experiments with LLC-bearing 
C57Bl/6J mice. On day 4 after tumor transplantation, the ani-
mals began receiving daily intramuscular injections of a sa-
line (control) or RNase solution ranging in concentration from 
0.1 g to 10 mg per kg of body weight (experiment).
Figure 1A demonstrates changes in the size of tumors dur-
ing the experiment depending on the RNase A dose. One can 
see a retardation of tumor growth in the LLC-bearing ani-
mals treated with RNase A at a dose ranging within 0.5–50 
g/kg. On day 8 after LLC transplantation, the tumor volume 
in these experimental groups was retarded by 20–40% when 
compared with the control. This difference was 23–33% on 
day 11 and 16% on day 13. No effect on tumor growth was 
observed in animal groups treated with RNase A at a dose 
above 0.5 mg/kg (Fig. 1A).
Intramuscular administration of RNase A to HA-1-bear-
ing A/Sn mice. To ensure that the antitumor activity of 
RNase A is not tumor-specific, we examined it on another 
model, hepatoma A1 in A/Sn mice. Since RNase A showed a 
marked activity on the LLC model at a dose ranging within 
0.5–50 g/kg, we also used this dose range in experiments 
with HA-1. The LLC-bearing С57Bl/6J mice were used as 
positive controls in these experiments. Beginning from day 8 
after tumor implantation, when the tumors became palpable, 
the mice with HA-1 or LLC received intramuscular injections 
of either a saline or RNase A solution at doses of 0.35, 0.7, and 
7 g/kg.
A comparison of tumor sizes in the control group and 
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RNase A showed an insignificant difference between the 
groups at the initial stage of treatment (day 10 after tumor 
transplantation) (Figs. 1B, 1C). On day 15 the tumor size in the 
groups of animals with HA-1 treated with RNase A at doses 
of 0.35 and 0.7 g/kg was 23% less than that in the control 
(Fig. 1C); in the groups of animals with LLC, it was 43% less 
(Fig. 1B). It is worth noting that the antitumor effect of RNase 
A on the LLC model did not depend on which day (4 or 8) the 
treatment began after implantation.
Intramuscular administration of DNase I to LLC-bearing 
C57Bl/6J mice and HA-1-bearing A/Sn mice. The antitu-
mor potential of DNase I was evaluated on two tumor mod-
els, LLC and HA-1. Starting at day 8 after the implantation of 
LLC to C57Bl/6J mice and HA-1 to A/Sn mice, the animals 
were injected with DNase I at a dose ranging within 0.02–2.3 
mg/kg. Measuring the tumor size showed that the injection 
of DNase I does not lead to the retardation of primary tumor 
growth.
EFFECTS OF RNASE A AND DNASE I ON 
METASTASIS DEVELOPMENT
The antimetastatic activities of RNase A and DNase I (their 
capability to decrease the number of metastases in target or-
gans) were estimated from (1) a histological analysis of target 
organs (the lungs for LLC and liver for HA-1), (2) a micro-
scopic examination of the metastasis number in the lungs of 
LLC-bearing animals, and (3) the liver weight alteration (he-
patic index) in animals with HA-1.
A HISTOLOGICAL ANALYSIS OF METASTASES 
IN THE LUNGS OF ANIMALS WITH LLC AND 
IN THE LIVER OF ANIMALS WITH HA-1 
Metastasis formation in the pulmonary tissue is a character-
istic feature of LLC. Distinct metastases and multiple groups 
of tumor cells were observed in the lungs of the control mice 
(Figs. 2A1, 2A2). Metastases of different sizes and irregular 
shapes were predominantly localized in the subpleural area. 
Some signs of mononuclear infiltration were observed in large 
metastases extending over several bronchi and large vessels 
(Fig. 2A1). Surface metastases were composed of two or three 
layers of tumor cells expanding along the pleura.
The development of heavy metastases in the liver is a 
characteristic feature of HA-1 progression. A multitude of 
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Fig. 1. Antitumor effect of RNAse A. A. The effect of RNase A on the 
growth of a primary LLC tumor in C57Bl/6J mice (concentration depen-
dence). B. The effect of RNase A in 0.35, 0.7 and 7 μg/kg dosages on 
the growth rate of a primary LLC tumor in C57Bl/6J mice. C. The effect 
of RNase A in 0.35, 0.7 and 7 μg /kg dosages on the growth rate of a 
primary HA-1 tumor in A/Sn mice
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Fig. 2. A. Metastases in the lungs of animals with LLC (A1 and A2) tumors 
and in the liver of animals with НА-1 (A3). B. Metastases in the lungs of 
animals with LLC tumors after treatment with DNase I (0.12 mg/kg) (B1) 
and RNase А (0.7 μg/kg) (B2 and B3). C. Metastasis in the liver of animals 
with HA-1 tumors after treatment with DNase I (0.02 mg/kg) (C1), 
DNase I (1.2 mg/kg) (C2) and RNase А (0.35 μg/kg) (C3)RESEARCH ARTICLES
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metastases of different sizes are found on histological sections 
of liver tissue (Fig. 2A3). We have revealed several morpho-
logic types of metastases, such as (1) distinctly bordered me-
tastases with pseudoglandular structures at the periphery of 
basophilic cells with pale densely packed cells at the center; 
(2) loose accumulations of basophilic oncocytes under hepatic 
capsule, and (3) small loose aggregations composed of dark 
basophilic oncocytes. Numerous mitoses in metastases, indi-
vidual disseminated tumor cells, the lymphocyte infiltration 
of liver parenchyma, and dystrophic changes and necroses of 
hepatocytes were observed in liver tissue of mice with HA-1 
(Fig. 2A3).
A HISTOLOGICAL ANALYSIS OF METASTASES IN THE 
LUNGS OF ANIMALS WITH LLC AND IN THE LIVER OF 
ANIMALS WITH HA-1 TREATED WITH ENZYMES 
The administration of RNase A or DNase I to animals with 
LLC induced dystrophic changes in metastases in the lungs 
(Fig. 2B). The morphologic parameters of these changes were 
identical in all groups irrespective of the dose: an increase in 
the number of necroses and apoptoses, a dystrophic transfor-
mation of oncocytes, and a considerable mononuclear infiltra-
tion of tumor extravasates and metastases (Fig. 2B, 1–3).
A histological analysis of the metastases in the liver tissue 
of mice with HA-1 treated with RNase A or DNase I at differ-
ent doses has shown clear morphologic changes with similar 
features. Both central and perifocal necroses, tissue edema, 
numerous hemorrhages, and clear mononuclear infiltration 
were observed in metastatic foci (Fig. 2C, 1–3). It should be 
noted that, unlike control animals, in which tumor infiltrates 
were found in the myocardium and kidney, metastases were 
not found in these organs of mice with HA-1 treated with the 
enzymes.
The state of immunity organs of animals with HA-1 also 
came under our notice. In particular, we observed some signs 
of the accidental involution of thymus, such as an increase in 
the amount of lymphocytes in the medulla or even an inver-
sion of the thymus layers. Similar alterations suggesting ex-
pressed antigenic stimulation were found in the spleen. The 
degree of manifestation of these signs of antigenic stimulation 
correlated with the enzyme dose.
Thus, a comparison between control animals with LLC or 
HA-1 and experimental ones treated with RNase A or DNase 
I has shown signs of induced pathomorphism of metastases 
manifested as the expressed dystrophic involution of tumor 
cells and an intensification of mononuclear infiltration.
COUNTING METASTASES IN THE LUNGS OF MICE WITH 
LLC FOLLOWING TREATMENT WITH ENZYMES
A microscopic examination of metastases on the surface of 
the LLC-bearing mouse lungs has shown that treating these 
animals with enzymes leads to a significant decrease in the 
metastasis number. The average number of metastases in 
groups of LLC-bearing mice treated with RNase A at doses 
of 0.5 g/kg, 0.7 g/kg, and 10 mg/kg were 14 ± 3, 15 ± 4, 
and 18 ± 4, respectively. The average number of metastases 
in groups of LLC-bearing mice treated with DNase I at doses 
of 0.02, 0.12, and 2.3 mg/kg were 10 ± 4, 16 ± 7, and 18 ± 
4, respectively, whereas in the untreated animal group this 
amount was 30 ± 5. Thus, the observed amount of metastases 
in groups of LLC-bearing mice treated with the enzymes was 
two- to threefold less than in the control.
An analysis of metastases in the lungs of LLC-bearing ani-
mals has shown not only morphologic changes and a decrease 
in their amount following treatment with the enzymes, but 
also an existential reduction of the metastasis area and an 
altered localization in the organ. Figure 3 shows the lungs of 
LLC-bearing animals without treatment (Fig. 3A) and after 
treatment with the enzymes (Figs. 3B, 3C). The decrease in 
both the amounts of metastatic foci and the area of metas-
tases is plain to see.
ESTIMATION OF THE THERAPEUTIC EFFICACY OF 
ENZYMES IN THE TREATMENT OF ANIMALS WITH HA-1
The diffuse boundaries of metastatic foci in hepatic paren-
chyma made it impossible to use microscopy for counting me-
tastases in the liver of animals bearing HA-1. Since the liver 
increases in weight during the metastasis development, we 
used the hepatic index (HI) reflecting disease severity and 
calculated as HI = (liver weight/body weight)  100% to esti-
mate the antimetastatic effects of the enzymes: the relative 
A
1 2
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C
5 mm
Fig. 3. Histotopo-
gramme of the lung 
lobes of C57Bl/6 mice 
with LLC. A. Animals 
which received injec-
tions of normal saline 
solution B. Animals 
which received injec-
tions of DNase I at 
a dosage of 0.02 
mg/kg. C. Animals 
which received injec-
tions of RNase A at a 
dosage of 0.7 μg/kg. 
Stained by hematoxylin 
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HI reduction in a group of treated animals compared to the 
control group served as the criterion of the therapeutic ef-
ficacy (TE). The data on the average liver increment (ALI) 
of animals with HA-1 compared to that of the healthy ones 
were used to estimate TE (Table 1). A noticeable decrease in 
HI in HA-1-bearing animals treated with the enzymes was 
observed relatively to the control. The TE value varied from 
30% to 42% in HA-1-bearing animals treated with RNase A 
and from 40% to 53% in those treated with DNase I.
DISCUSSION
As was mentioned in the Introduction, the largest represent-
ative of the RNase A family, pancreatic RNase A, demon-
strated weak antitumor activity at high doses (above 10 mg/
kg) [14, 15] and DNase I was capable of metastasis growth 
suppression [21, 22].
In this work, we studied both the antitumor and antimeta-
static activities of RNase A in vivo using doses ranging from 
0.1 g/kg to 10 mg/kg. We have shown that the intramuscu-
lar administration of RNase A at doses ranging within 0.5–50 
g/kg leads to the retardation of primary tumor growth by 
20–40% with a more pronounced effect at early stages of tu-
mor development (on the 8th day). Doses above 0.5 mg/kg, 
RNase A did not affect the tumor growth, which conforms 
to the previously reported data of other authors [17, 25]. The 
administration of DNase I at a dose in the range of 0.02–2.3 
mg/kg did not result in any retardation of the primary tumor 
growth. We found that the intramuscular administration of 
any of these enzymes led to a considerable (two- to three-
fold) decrease in both the amount and size of metastases in 
the lungs of animals with LLC. In the case of hepatoma HA-1, 
the intramuscular administration of either RNase A or DNase 
I led to a decrease in the liver weight relatively to the con-
trol, with a therapeutic efficacy of 30–42% for RNase A and 
40–53% for DNase I. A histological analysis of the lungs and 
liver has shown that both enzymes similarly destroy tumor 
cells and increase the number of necroses and apoptoses in 
metastatic foci. Our data make it possible for us to conclude 
that both enzymes have high antimetastatic activity.
Yet there is no commonly accepted mechanism of antitu-
mor activity for ribonucleases. The antitumor effect of RNase 
A that we observed can occur due to (1) the degradation of 
encoding intracellular RNAs and, as a consequence, (a) the 
arrest of protein synthesis [26, 27] and (b) the alteration of 
gene expression profile via RNA cleavage products [28]; (2) 
the degradation of noncoding RNAs (pre-miRNAs, miRNAs, 
and siRNAs) [2, 29]; (3) the destabilization of the RNA struc-
ture [30]; (4) the blockage of RNA functions [31]; (5) the influ-
ence on signaling pathways [32–34]; and (6) the cutoff of un-
controlled potassium influx via calcium-dependent potassium 
channels of tumor cells [35]. Also, one cannot exclude other as 
of yet unknown mechanisms.
We hypothesize that the antimetastatic effects of RNase A 
and DNase I, as well as the antitumor effect of RNase A, are 
associated with the main function of these enzymes (the nu-
cleic acid cleavage). Nevertheless, we cannot claim definitively 
that the antitumor effect of RNase A happens via the degrada-
tion of tumor intracellular RNAs, because a great pool of data 
univocally evidences for the binding of the enzyme penetrating 
into the cell with the ribonuclease inhibitor [17].
Putative targets for RNase A are RNAs circulating in blood 
plasma, including pre-miRNAs and miRNAs implicated in the 
control of oncogenesis and invasion [3, 36, 37]. The expression 
of most miRNAs implicated in the control of tumor-specific 
genes is known to be disordered [38, 39]. In particular, the 
elevation of miR-9 expression in breast cancer leads to a de-
crease in the E-cadherin level and invasion enhancement [40]. 
It was shown that the level of miR-184 possessing a stimula-
tory effect on the antiapoptotic and proliferative potential of 
tumor cells is increased in the plasma of patients with squa-
mous cell carcinoma of thetongue [41]. Putative targets for 
DNase I are extracellular tumor-derived DNAs that, accord-
ing to the genometastatic theory, are capable of transfection 
of distant cells, thus providing metastatic progression in pri-
marily unaffected organs [4].
Some small peptides show antitumor [42] and immunos-
timulating [43, 44] activities at extremely low doses; however, 
it is not really understood how they act. We cannot exclude 
that the antimetastatic effects of low doses of RNase A and 
DNase I that we found in this study might be associated with 
the formation of biogenic peptides due to the proteolysis of 
these enzymes in blood.
The disappearance of the antitumor activity of RNase A 
at doses above 0.5 mg/kg or upon prolonged administration 
(the observed decrease of antitumor effect on day 13 of tu-
mor development) might be associated with the specific anti-
RNase A antibody production. This suggestion is supported 
by signs of antigenic stimulation following the administra-
tion of RNase A: there is an increase in the number of lym-
phocytes in the medullar layer of thymus and in the spleen, 
Table 1. Hepatic index (HI), average liver increment (ALI), and treatment efficiency (TE) of the A/Sn mice bearing HA-1
Control Healthy 
mice
RNase A, g/kg DNase I, mg/kg
0.35 0.7 7 0.02 0.23 0.12 2.3
(1)HI, % 6.7±0.3 4.5 5.9±0.2 6.0±0.2 5.9±0.2 5.5±0.3 5.8±0.2 5.6±0.3 5.7±0.2
(2)ALI, % 2.2 – 1.3 1.5 1.4 1.0 1.3 1.1 1.2
(3)TE, % 0 – 42 30 38 53 40 52 46
(1) HI = (liver weight/mouse weight)  100%;
(2) ALI (%) = HIexperiment – HIhealthy = 4.5%; 
(3)TE (%) = 100 – ALIexperiment / ALIcontrol  100.RESEARCH ARTICLES
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an inversion of thymus layers, and a mononuclear infiltration 
of metastatic foci.
CONCLUSIONS
We have shown that the intramuscular administration of 
RNase A or DNase I has a systemic effect on malignant tu-
mors, which is manifested as a retardation of tumor growth 
(RNase A), a decrease in the amount and area of metastases, 
and destructive changes in metastatic foci (both enzymes). 
The most effective antimetastatic doses of the enzymes had 
no toxic effect on animals. Our data make it possible to rec-
ommend using RNase A and DNase I in the supplementary 
therapy of metastasizing tumors.  
The study was supported by the Russian Foundation for 
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